Tick (check) box to add article to PDF "basket"
Investigating the genetic footprint that drug resistance causes in HIV, researchers in Europe have discovered that compensatory polymorphisms enable resistant viruses to survive. Presented in the journal Retrovirology, the study was supported in part by three EU-funded projects: VIROLAB, EURESIST and CHAIN. Both the VIROLAB ('A virtual laboratory for decision support in viral diseases treatment') and EURESIST ('Integration of viral genomics with clinical data to predict response to anti-HIV treatment') projects were funded under the 'Information society technologies' (IST) Thematic area of the EU's Sixth Framework Programme (FP6) to the tune of EUR 3.3 million and EUR 2.1 million, respectively. CHAIN ('Collaborative HIV and anti-HIV drug resistance network') has received almost EUR 10 million under the Health Theme of the EU's Seventh Framework Programme (FP7).
Published: 24 October 2012
In June 2011, medical regulators gave the go-ahead for trials in humans of
a potential new anti-HIV drug. The drug was produced in genetically modified
Published: 18 June 2012
Life expectancy for HIV patients treated with antiretroviral drugs, now considered common course in treating the virus, can expect to live considerably longer lives, new research from the United Kingdom shows. This study was funded in part by the EUROCOORD ('European network of HIV/AIDS cohort studies to coordinate at European and international level clinical research on HIV/AIDS') project, which is backed with EUR 12 million under the Health Theme of the EU's Seventh Framework Programme (FP7). EUROCOORD brings together a number of other networks, all of which have played a central role in developing our understanding, progression and treatment of HIV.
Published: 1 June 2012
An international team of researchers has discovered that a protein responsible for protecting some of our body's immune cells from the most common and virulent form of HIV succeeds in its quest because it starves the virus of the molecular building blocks it requires to replicate. The study, published in the journal Nature Immunology, was supported in part by a European Research Council (ERC) grant under the EU's Seventh Framework Programme (FP7). The results could help us understand why some anti-HIV drugs are more effective than others.
Published: 1 March 2012
Researchers in the United Kingdom have shed new light on how the body's proteins can fight the human immunodeficiency virus (HIV-1). The study, presented in journal Nature, was funded in part by the NIMBL ('Nuclease immune mediated brain and Lupus-like conditions: natural history, pathophysiology, diagnostic and therapeutic modalities with application to other disorders of autoimmunity') project, which is backed with EUR 5.4 million under the Health Theme of the EU's Seventh Framework Programme (FP7).
Published: 2 December 2011